GeNeuro (DB:GEM) - Stock Price, News & Analysis

GEM Stock Overview

A clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases.

About the company

GEM fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Risk Analysis

Negative shareholders equity

Makes less than USD$1m in revenue (€0)

Highly volatile share price over the past 3 months

Earnings have declined by 8.6% per year over past 5 years

+ 2 more risks

GeNeuro SA Competitors

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€649.9k

Medigene

XTRA:MDG1

€31.6m

4SC

DB:VSC

€58.0m

Price History & Performance

Summary of all time highs, changes and price drops for GeNeuro
Historical stock prices
Current Share Price	€0.049
52 Week High	€2.42
52 Week Low	€0.039
Beta	0.37
11 Month Change	-2.40%
3 Month Change	-81.23%
1 Year Change	-96.26%
33 Year Change	-98.63%
5 Year Change	-98.64%
Change since IPO	-99.59%

Recent updates

Shareholder Returns

	GEM	DE Biotechs	DE Market
7D	8.0%	2.6%	4.5%
1Y	-96.3%	-16.4%	13.4%

Return vs Industry: GEM underperformed the German Biotechs industry which returned -16.4% over the past year.

Return vs Market: GEM underperformed the German Market which returned 13.4% over the past year.

Price Volatility

Is GEM's price volatile compared to industry and market?
GEM volatility
GEM Average Weekly Movement	47.6%
Biotechs Industry Average Movement	6.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: GEM's share price has been volatile over the past 3 months.

Volatility Over Time: GEM's weekly volatility has increased from 30% to 48% over the past year.

About the Company

Founded	Employees	CEO	Website
2006	17	Jesus Martin-Garcia	www.geneuro.com

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301.

GeNeuro SA Fundamentals Summary

How do GeNeuro's earnings and revenue compare to its market cap?
GEM fundamental statistics
Market cap	€2.53m
Earnings (TTM)	-€14.76m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Is GEM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GEM income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€14.76m
Earnings	-€14.76m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.50
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-93.4%

How did GEM perform over the long term?

See historical performance and comparison

GEM Stock Overview

Rewards

Risk Analysis

GeNeuro SA Competitors

XTRA:CNW

€6.5m

XTRA:T5O

€649.9k

XTRA:MDG1

€31.6m

DB:VSC

€58.0m

Price History & Performance

Recent News & Updates

GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome

GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024

New minor risk - Financial data availability

Geneuro SA Announces Appointments of Board of Directors

GeNeuro SA has completed a Follow-on Equity Offering in the amount of €4.900246 million.

Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications

Recent updates

GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome

GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024

New minor risk - Financial data availability

Geneuro SA Announces Appointments of Board of Directors

GeNeuro SA has completed a Follow-on Equity Offering in the amount of €4.900246 million.

Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications

New major risk - Revenue and earnings growth

Forecast to breakeven in 2024

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

New major risk - Negative shareholders equity

GeNeuro SA Announces Recent Study Demonstrates the Strong Link Between SARS-CoV-2 Infection and HERV-W Activation in Hospitalized Psychotic Patients

New major risk - Share price stability

GeNeuro SA to Report First Half, 2023 Results on Sep 29, 2023

Insufficient new directors

GeNeuro SA, Annual General Meeting, Jun 14, 2023

Insufficient new directors

GeNeuro SA Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-Covid Assessing Temelimab

Geneuro’S Protect-Ms Phase 2 Trial Data, Presented At the Ectrims 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in Ms

GeNeuro Will Present Phase IIb Safety and Efficacy Data on Temelimab from its ProTEct-MS Study at the 38thCongress of the European Committee for Treatment and Research in Multiple Sclerosis

Geneuro Is Granted Authorization by the Swiss Health Authority to Initiate A Phase II Study Evaluating Temelimab in Patients with Severe Neuropsychiatric Post-Covid Syndromes

Insufficient new directors

GeNeuro SA, Annual General Meeting, May 31, 2022

GeNeuro and Fondamental Foundation Announce the First Results of the Collaboration for the Development of Diagnostic and Therapeutic Options for Patients with Post-Covid Neuropsychiatric Syndromes

GeNeuro Announces the Completion of Its ProTEct-MS Study and Confirms the March Timeline for Top-line Results

Geneuro Sa unveils Additional Results from the Preclinical Research Program in Amyotrophic Lateral Sclerosis (Als) Developed in Partnership with the National Institute of Neurological Disorders and Stroke

Geneuro Receives EUR 6.4 Million in Funding from the Swiss Government for the Development of Temelimab Against Long-Covid

GeNeuro Announces First Patient Having Finished the ProTEct-MS Study at the Karolinska Institutet’s Academic Specialist Center Has Entered the Study Extension

Insufficient new directors

GeNeuro Announces the Publication in Multiple Sclerosis of Results From CHANGE-MS and ANGEL-MS Studies

Geneuro Presents Data Supporting Pathogenic Role of an Endogenous Retroviral Protein (HERV-W ENV) in Post-Covid Neuropsychiatric Syndrome

GeNeuro SA Announces Independent Drug Safety Monitoring Board (Dsmb) Has Concluded the Phase 2 Trial of Temelimab in Ms Patients

GeNeuro Completes Patient Recruitment in Temelimab Phase 2 Multiple Sclerosis Trial at the Karolinska Institutet’s Academic Specialist Center (ASC)

New 90-day high: €3.85

New 90-day low: €2.57

New 90-day low: €2.94

New 90-day low: €3.01

GeNeuro SA Announces Management Changes

GeNeuro SA to Report First Half, 2020 Results on Sep 29, 2020

Shareholder Returns

Price Volatility

About the Company

GeNeuro SA Fundamentals Summary

0.0x

-0.2x

Earnings & Revenue